Navigation Links
Accera, Inc. Donates $50,000 to the Alzheimer's Foundation of America for National Memory Screening Day
Date:10/24/2011

BROOMFIELD, Colo., Oct. 24, 2011 /PRNewswire/ -- Accera, Inc., a biotech company specializing in cognitive health, announced today the company has donated $50,000 to the Alzheimer's Foundation of America (AFA) for sponsorship of its "National Memory Screening Day" (NMSD) during National Alzheimer's Disease Awareness Month.  These funds will be used to further the AFA's efforts to educate and support individuals with Alzheimer's disease (AD) and their families, especially about the importance of early detection of memory problems.

Eric J. Hall, founding president and CEO of AFA, said, "We're grateful that despite the difficult economy, Accera continues to demonstrate its generous commitment to individuals and their families facing Alzheimer's disease now or in the future.  It's a public health crisis that requires corporate engagement."

NMSD, an annual initiative sponsored by AFA, provides free, confidential, memory screenings to individuals concerned about memory loss with the objective of early detection and intervention.  Qualified healthcare professionals offer the face-to-face screenings and distribute educational materials about memory concerns and successful aging in communities across the nation on November 15.

Samuel Henderson, Ph.D., vice president of research and development for Accera, stated, "On behalf of the Accera team, we're happy to contribute to AFA's ongoing efforts of helping those affected by Alzheimer's and raise awareness about the options available to patients and their caregivers."  He continued, "It's our hope that through continued awareness initiatives such as NMSD, we can better educate patients and their families about this devastating disease."

About Alzheimer's disease
AD significantly impacts millions of family members and other caregivers – mentally, physically and financially.  The national Family Caregiver Alliance estimates that approximately 80 percent of caregivers provide unpaid assistance seven days a week.  With the lack of innovative new medications for AD, both patients and caregivers are seeking alternatives to improve quality of life.

About Axona®
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells.  With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies.  For more information about Axona, please visit www.about-axona.com or contact a doctor who is familiar with the product.

About Accera, Inc.  
Accera, Inc. is a privately held commercial-stage cognitive health company that developed and now markets Axona in the US.  Axona is a prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease.  In clinical trials, Axona has been shown to safely improve cognitive function and memory in AD patients.  Axona addresses the hypometabolism or defective metabolism of glucose that occurs in those areas of the brain that are involved in Alzheimer's disease.  Accera engages in research, development and commercialization of other clinical applications for Axona.

For more information about Accera, please visit www.accerapharma.com.Contacts:Accera, Inc.
(303) 999-3705
Bill Poncy
VP Commercial Development
bponcy@accerapharma.com

Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach

amielach@tiberend.com
or
Madeleine Desmond

mdesmond@tiberend.com
'/>"/>

SOURCE Accera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accera, Inc. to Support the Alzheimers Foundation of Americas National Memory Screening Day Through On-line Awareness Effort
2. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
3. Accera, Inc. to Present at Upcoming Investor Conferences
4. Dr. Thomas Werner Elected to Accera, Inc.s Board of Directors
5. Accera, Inc. Sponsors Alzheimers Associations 2009 ICAD Conference
6. Accera, Inc. Completes $35 Million Series C Financing
7. The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan
8. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
9. Vita-Tech International, Inc. Donates One Ton of Vitamins To Polio Treatment Centers in Guinea, West Africa
10. GeneGo Donates Proprietary Cytokine Pathway Maps to ISICR
11. SANYO Donates Air Purification Systems Effective Against Flu Viruses to New York Airports and Schools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... has initiated a global Phase 2b induction study ... that targets alpha4beta7 integrin. The aim of this ... evaluate the safety/tolerability and efficacy of PTG-100 in ... to severe active disease. "We ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. Pavlov, ... MD , president and CEO of The Feinstein ... an analysis of how the nervous system regulates the ... develop bioelectronic medicine devices to treat disease ... Nature Neuroscience . The paper examines various ...
(Date:1/14/2017)... ... January 14, 2017 , ... Seattle-based Phase ... end-to-end genome assemblies to researchers around the globe. Long considered a “holy ... answering a wide range of scientific questions. The announcement was made today ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology:
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/15/2016)... LONDON , Dec. 15, 2016 /PRNewswire/ ... the driving experience, health wellness and wellbeing ... As one in three new passenger vehicles ... voice recognition, gesture recognition, heart beat monitoring, ... eyelid monitoring, facial monitoring, and pulse detection. ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
Breaking Biology News(10 mins):